Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
© 2024. The Author(s)..
ZUMA-1 safety management cohort 6 investigated the impact of prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab on the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs) following axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Prior analyses of cohort 6 with limited follow-up demonstrated no Grade ≥3 CRS, a low rate of NEs, and high response rates, without negatively impacting axi-cel pharmacokinetics. Herein, long-term outcomes of cohort 6 (N = 40) are reported (median follow-up, 26.9 months). Since the 1-year analysis (Oluwole, et al. Blood. 2022;138[suppl 1]:2832), no new CRS was reported. Two new NEs occurred in two patients (Grade 2 dementia unrelated to axi-cel; Grade 5 axi-cel-related leukoencephalopathy). Six new infections and eight deaths (five progressive disease; one leukoencephalopathy; two COVID-19) occurred. Objective and complete response rates remained at 95% and 80%, respectively. Median duration of response and progression-free survival were reached at 25.9 and 26.8 months, respectively. Median overall survival has not yet been reached. Eighteen patients (45%) remained in ongoing response at data cutoff. With ≥2 years of follow-up, prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab continued to demonstrate CRS improvement without compromising efficacy outcomes, which remained high and durable.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Bone marrow transplantation - 59(2024), 3 vom: 07. März, Seite 366-372 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Oluwole, Olalekan O [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41409-023-02169-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366678353 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366678353 | ||
| 003 | DE-627 | ||
| 005 | 20240311232054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41409-023-02169-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM366678353 | ||
| 035 | |a (NLM)38177222 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Oluwole, Olalekan O |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a ZUMA-1 safety management cohort 6 investigated the impact of prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab on the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs) following axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Prior analyses of cohort 6 with limited follow-up demonstrated no Grade ≥3 CRS, a low rate of NEs, and high response rates, without negatively impacting axi-cel pharmacokinetics. Herein, long-term outcomes of cohort 6 (N = 40) are reported (median follow-up, 26.9 months). Since the 1-year analysis (Oluwole, et al. Blood. 2022;138[suppl 1]:2832), no new CRS was reported. Two new NEs occurred in two patients (Grade 2 dementia unrelated to axi-cel; Grade 5 axi-cel-related leukoencephalopathy). Six new infections and eight deaths (five progressive disease; one leukoencephalopathy; two COVID-19) occurred. Objective and complete response rates remained at 95% and 80%, respectively. Median duration of response and progression-free survival were reached at 25.9 and 26.8 months, respectively. Median overall survival has not yet been reached. Eighteen patients (45%) remained in ongoing response at data cutoff. With ≥2 years of follow-up, prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab continued to demonstrate CRS improvement without compromising efficacy outcomes, which remained high and durable | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a axicabtagene ciloleucel |2 NLM | |
| 650 | 7 | |a U2I8T43Y7R |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Antigens, CD19 |2 NLM | |
| 700 | 1 | |a Forcade, Edouard |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a de Guibert, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Vose, Julie M |e verfasserin |4 aut | |
| 700 | 1 | |a Bartlett, Nancy L |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Deol, Abhinav |e verfasserin |4 aut | |
| 700 | 1 | |a McSweeney, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Goy, Andre H |e verfasserin |4 aut | |
| 700 | 1 | |a Kersten, Marie José |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobson, Caron A |e verfasserin |4 aut | |
| 700 | 1 | |a Farooq, Umar |e verfasserin |4 aut | |
| 700 | 1 | |a Minnema, Monique C |e verfasserin |4 aut | |
| 700 | 1 | |a Thieblemont, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Timmerman, John M |e verfasserin |4 aut | |
| 700 | 1 | |a Stiff, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Avivi, Irit |e verfasserin |4 aut | |
| 700 | 1 | |a Tzachanis, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Vardhanabhuti, Saran |e verfasserin |4 aut | |
| 700 | 1 | |a Nater, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Rhine R |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Harry |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jenny J |e verfasserin |4 aut | |
| 700 | 1 | |a van Meerten, Tom |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bone marrow transplantation |d 1986 |g 59(2024), 3 vom: 07. März, Seite 366-372 |w (DE-627)NLM012638250 |x 1476-5365 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:3 |g day:07 |g month:03 |g pages:366-372 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41409-023-02169-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2024 |e 3 |b 07 |c 03 |h 366-372 | ||